The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation

Cancer Research

Volumn 63, Issue 16, 2003, Pages 5143-5150

  Rad, Ariel N ^a   Pollara, Gabriele ^a   Sohaib, S M Afzal ^a   Chiang, Cheryl ^a   Chain, Benjamin M ^a   Katz, David R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CD86 ANTIGEN; CHLORAMBUCIL; CYTARABINE; CYTOKINE; INTERLEUKIN 12; MELPHALAN;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA DAMAGE; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DEATH; COCULTURE TECHNIQUES; DENDRITIC CELLS; DNA DAMAGE; HUMANS; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; NEOPLASMS; T-LYMPHOCYTES; U937 CELLS; UP-REGULATION;

EID: 0043016184     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Collins, R. H., Jr., Shpilberg, O., Drobyski, W. R., Porter, D. L., Giralt, S., Champlin, R., Goodman, S. A., Wolff, S. N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J. H., and Nemunaitis, J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol., 15: 433-444, 1997.
2. Horowitz, M. M., Gale, R. P., Sondel, P. M., Goldman, J. M., Kersey, J., Kolb, H. J., Rimm, A. A., Ringden, O., Rozman, C., and Speck, B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75: 555-562, 1990.
3. Clark, F. J., and Chakraverty, R. Role of dendritic cells in graft-versus-host disease. J. Hematother. Stem Cell Res., 11: 601-616, 2002.
4. Childs, R., Clave, E., Contentin, N., Jayasekera, D., Hensel, N., Leitman, S., Read, E. J., Carter, C., Bahceci, E., Young, N. S., and Barrett, A. J. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood, 94: 3234-3241, 1999.
5. Montagna, D., Maccario, R., Locatelli, F., Rosti, V., Yang, Y., Farness, P., Moretta, A., Comoli, P., Montini, E., and Vitiello, A. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood, 98: 3359-3366, 2001.
6. Ishii, K. J., Suzuki, K., Coban, C., Takeshita, F., Itoh, Y., Matoba, H., Kohn, L. D., and Klinman, D. M. Genomic DNA released by dying cells induces the maturation of APCs. J. Immunol., 167: 2602-2607, 2001.
7. Carella, A. M., Champlin, R., Slavin, S., McSweeney, P., and Storb, R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant., 25: 345-350, 2000.
8. Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Korbling, M., Keating, M., Kantarjian, H., and Champlin, R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89: 4531-4536, 1997.
9. Olavarria, E., and Kanfer, E. J. Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells. Curr. Opin. Hematol., 7: 191-196, 2000.
10. Khouri, I. F., Keating, M., Korbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., Donato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A., and Champlin, R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol., 16: 2817-2824, 1998.
11. Steinman, R. M., Turley, S., Mellman, I., and Inaba, K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med., 191: 411-416, 2000.
12. Cella, M., Engering, A., Pinet, V., Pieters, J., and Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature (Lond.), 388: 782-787, 1997.
13. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., and Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184: 747-752, 1996.
14. Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kampgen, E., Romani, N., and Schuler, G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med., 184: 741-746, 1996.
15. Gallucci, S., Lolkema, M., and Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med., 5: 1249-1255, 1999.
16. Matzinger, P. The danger model: a renewed sense of self. Science (Wash. DC), 296: 301-305, 2002.
17. Basu, S., Binder, R. J., Suto, R., Anderson, K. M., and Srivastava, P. K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol., 12: 1539-1546, 2000.
18. Somersan, S., Larsson, M., Fonteneau, J. F., Basu, S., Srivastava, P., and Bhardwaj, N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J. Immunol., 167: 4844-4852, 2001.
19. Melcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., and Vile, R. G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med., 4: 581-587, 1998.
20. Rutault, K., Alderman, C., Chain, B. M., and Katz, D. R. Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic. Biol. Med., 26: 232-238, 1999.
21. Langenkamp, A., Messi, M., Lanzavecchia, A., and Sallusto, F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol., 1: 311-316, 2000.
22. Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., and Henson, P. M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Investig., 101: 890-898, 1998.
23. Voll, R. E., Herrmann, M., Roth, E. A., Stach, C., Kalden, J. R., and Girkontaite, I. Immunosuppressive effects of apoptotic cells. Nature (Lond.), 390: 350-351, 1997.
24. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
25. Wyllie, A. H. The biology of cell death in tumours. Anticancer Res., 5: 131-136, 1985.
26. Wyllie, A. H., Apoptosis: An overview. Brit. Med. Bull., 53: 451-465, 1997.
27. Nikitina, E. Y., and Gabrilovich, D. I. Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int. J. Cancer, 94: 825-833, 2001.
28. Tong, Y., Song, W., and Crystal, R. G. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res., 61: 7530-7535, 2001.
29. Le, H. N., Lee, N. C., Tsung, K., and Norton, J. A. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J. Immunol., 167: 6765-6772, 2001.
30. Passmore, J. S., Lukey, P. T., and Ress, S. R. The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen-specific cytotoxic T-cell function. Immunology, 102: 146-156, 2001.
31. Chen, Z., Moyana, T., Saxena, A., Warrington, R., Jia, Z., and Xiang, J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer, 93: 539-548, 2001.
32. Troyano, A., Fernandez, C., Sancho, P., de Blas, E., and Aller, P. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J. Biol. Chem., 276: 47107-47115, 2001.
33. Xia, C. Q., and Kao, K. J. Heparin induces differentiation of CD1a+ dendritic cells from monocytes: phenotypic and functional characterization. J. Immunol., 168: 1131-1138, 2002.
34. Hoffmann, T. K., Meidenbauer, N., Dworacki, G., Kanaya, H., and Whiteside, T. L. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res., 60: 3542-3549, 2000.
35. Gould, D. S., and Auchincloss, H., Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol. Today, 20: 77-82, 1999.
36. Lechler, R. I., and Batchelor, J. R. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J. Exp. Med., 155: 31-41, 1982.
37. Cote, I., Rogers, N. J., and Lechler, R. I. Allorecognition. Transfus. Clin. Biol., 8: 318-323, 2001.
38. Mullen, C. A. Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation. Leuk. Lymphoma, 43: 503-510, 2002.
39. Henry, F., Boisteau, O., Bretaudeau, L., Lieubeau, B., Meflah, K., and Gregoire, M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res., 59: 3329-3332, 1999.
40. Braess, J., Reich, K., Willert, S., Strutz, F., Neumann, C., Hiddemann, W., and Wormann, B. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL). Ann. Hematol., 75: 227-230, 1997.
41. Ronnblom, L. E., Alm, G. V., and Oberg, K. E. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med., 115: 178-183, 1991.
42. Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., and Marshak-Rothstein, A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (Lond.), 416: 603-607, 2002.
43. Smyth, M. J., Godfrey, D. I., and Trapani, J. A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol., 2: 293-299, 2001.
44. Gallucci, S., and Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol., 13: 114-119, 2001.